Company: LENZ
Filing Date: 2025-04-28
Form Type: DEF 14A
Source: 0001193125-25-100630
Chunk: 12

Company: LENZ Therapeutics, Inc.
Filing Date: 2025-04-28
Form: DEF 14A
Chunk 12
---
apkin(1)(2) |     | III   |     |     | 57 |     | Director                                                    |     |           2023 |     |         2025 |     |          2027 |
| Zach Scheiner(1)(3)        |     | III   |     |     | 48 |     | Director                                                    |     |           2024 |     |         2025 |     |          2027 |
| Frederic Guerard(2)(3)     |     | I     |     |     | 52 |     | Director                                                    |     |           2024 |     |         2025 |     |          2028 |
| James McCollum             |     | I     |     |     | 70 |     | Director                                                    |     |           2024 |     |         2025 |     |          2028 |
| Continuing Directors       |     |       |     |     |    |     |                                                             |     |                |     |              |     |               |
| Evert Schimmelpennink      |     | II    |     |     | 53 |     | Chief Executive Officer, President, Secretary, and Director |     |           2024 |     |         2026 |     |             — |
| Jeff George(1)             |     | II    |     |     | 51 |     | Chairperson                                                 |     |           2024 |     |         2026 |     |             — |
| Shelley Thunen(2)(3)       |     | II    |     |     | 72 |     | Director                                                    |     |           2024 |     |         2026 |     |             — |

| (1) | Member of the nominating and corporate governance committee. |

| (2) | Member of the compensation committee. |

| (3) | Member of the audit committee. |

**Nominees for Director Kimberlee C. Drapkinhas served a member of our board of directors since July 2023. Ms. Drapkin served as interim president and chief executive officer of Graphite Bio, Inc. from August 2023 through the closing of the Merger. Ms. Drapkin has over 25 years of experience working with private and publicly traded biotechnology and pharmaceutical companies, including building and leading finance functions, raising capital, and leading strategic financial planning. Prior to